VYNE Therapeutics Share Holder Equity 2016-2025 | VYNE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

VYNE Therapeutics share holder equity from 2016 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

VYNE Therapeutics share holder equity from 2016 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$77.5B
Zoetis (ZTS)	$65.6B
Daiichi Sankyo, - (DSNKY)	$46.1B
Takeda Pharmaceutical (TAK)	$45.9B
BeOne Medicines - (ONC)	$32B
Sandoz Group AG (SDZNY)	$25.2B
Summit Therapeutics (SMMT)	$19.6B
Merck (MKKGY)	$16.6B
Shionogi (SGIOY)	$14.4B
United Therapeutics (UTHR)	$13.2B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.5B
Corcept Therapeutics (CORT)	$7.4B
Madrigal Pharmaceuticals (MDGL)	$7.3B
Stevanato Group S.p.A (STVN)	$7.3B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Procaps Group, S.A (PROCF)	$3.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B